Outcome The overall mortality rate was 6.4% (58/912). 232 patients (25.4%) were admitted to the intensive care unit in the early recovery phase immediately following surgery. 87 patients (9.5%) ultimately required a subsequent “re-operation.” 72,4% of these re-laparotomies were “on-demand” follow-up procedures that came about unexpectedly and 19,5% were planned re-operations. Overall, 8% of these patients underwent an “open abdomen” procedure. The median post-operative day for a subsequent re-operation in the “open abdomen” group was 3.7 days (range 2–5). According to univariate statistical analysis (see Table 8), a critical clinical AR-13324 solubility dmso condition (severe sepsis and septic shock) upon hospital
GSK2118436 solubility dmso BI-D1870 clinical trial admission was the most significant risk factor for death; indeed, the rate of patient mortality was 31.7% (40/126) among critically ill patients (patients presenting with septic shock and severe sepsis upon admission), while the mortality rate was only 2.2% (18/786) for clinically stable patients (p < 0.0001). Table 8 Risk factors for death during hospitalization Risk Factors Mortality rate in patients with risk factor Mortality rate in patients without risk factor P Critical ill condition at the admission (Severe sepsis, septic shock) 31,7% (40/126) 2,2% (18/786) <0,0001 Healthcare-associated infection
12,9% (20/155) 5% (38/757) 0,0015 Non-appendicular origin (10,1%) 57/562 (0,3%) 1/350 <0,0001 Generalized peritonitis 12,4% (42/338) 2,8% (16/574) <0,0001 Delay in the initial intervention (>24 hours) 11% (29/263) 4,5% (29/643) 0,0013 Comorbidity Malignancy 13,8% (21/152) 4,9% (37/760) 0,0003 Serious cardiovascular disease 17,4% (25/144) 3,6% (28/768) <0,0001 For patients with healthcare-associated and community-acquired infections, the mortality rates were 12.9% (20/155) and 5% (38/757), respectively (p = 0.0015). The mortality rate was 12.4% (42/338) for patients with generalized peritonitis and only 2.8% (16/574) for patients with localized peritonitis or abscesses (p < 0.001). The mortality rate was 10.1% (57/562)
for patients with infections of non-appendicular origin and only 0,3% (1/350) for patients Paclitaxel chemical structure with infections of appendicular origin (p < 0.001). Malignancy and serious cardiovascular disease were the most significant comorbidities associated with an elevated mortality rate. For those patients affected by malignancy, the mortality rate was 13.8% (21/152), marking a substantial increase from the 4.9% mortality rate (37/760) for patients who did not suffer from malignancy (p = 0.0003). Similarly, the mortality rates for patients with and without serious cardiovascular disease were 17.4% (25/144) and 3.6%, respectively (28/768) (p < 0.0001). Mortality rates did not vary to a statistically significant degree between patients who received adequate source control and those who did not.
No related posts.